EGFR and non-small cell lung carcinoma: The median OS in clinical trials involving first- or second-generation EGFR-TKIs has been 19.3–33.2 months.23,24 Lee et al. found that among 166 patients who derived clinical benefits from the use of first-generation EGFR-TKIs (gefitinib and erlotinib), 26% experienced central nervous system failure.25 Additionally, EGFR-mutant patients with BM survived longer18 and showed a higher incidence of metachronous BM than patients with NSCLC harboring wild-type EGFR.